Zepbound vs Mounjaro: Same Drug? Uses, Doses, Coverage and Cost (2026)

Short answer: Zepbound and Mounjaro are the same medicine, tirzepatide from Eli Lilly, at the same 2.5 mg to 15 mg strengths.^[1][2] The FDA approved them as two separate products for different uses: Mounjaro for type 2 diabetes (since May 13, 2022) and Zepbound for chronic weight management (since November 8, 2023) and obstructive sleep apnea with obesity.^[3] That difference in the label, not the drug, is what drives insurance coverage and price, and whether one can stand in for the other is a decision for your prescriber.

Whichever one a person takes, eating well on a smaller appetite matters just as much, which is the subject of our guide to what to eat when you're eating less. General information, not medical advice. Everything below comes from the two FDA labels, Lilly's own coverage and price pages, and CMS, as of November 13, 2026.

Zepbound vs Mounjaro at a glance

	Zepbound	Mounjaro
Maker and active ingredient	The same: Eli Lilly; tirzepatide, which activates the GIP and GLP-1 receptors[1][2]
FDA-approved uses (date)	Chronic weight management in adults with obesity, or overweight plus a weight-related condition (November 8, 2023); moderate to severe obstructive sleep apnea in adults with obesity (December 20, 2024)[3][1]	Blood sugar control in adults with type 2 diabetes (May 13, 2022) and in children 10 and older (December 19, 2025); lowering the risk of heart attack, stroke and cardiovascular death in adults with type 2 diabetes at high cardiovascular risk (August 27, 2026)[3][2]
Who it is for	Adults only[1]	Adults and children 10 and older with type 2 diabetes[2]
Forms on the label	Single-dose pen, single-dose vial, 4-dose KwikPen[1]	Single-dose pen, single-dose vial, 4-dose multi-dose vial, 4-dose KwikPen[2]
Label dose range	Starts at 2.5 mg; maintenance 5, 10 or 15 mg (10 or 15 mg for sleep apnea); maximum 15 mg[1]	Starts at 2.5 mg, raised in 2.5 mg steps; maximum 15 mg in adults and 10 mg in children; since August 2026, 2.5 mg may also be an ongoing dose[2][3]
Headline trials	SURMOUNT-1, 72 weeks: body weight −15.0%, −19.5% and −20.9% on 5, 10 and 15 mg vs −3.1% on placebo[4]	SURPASS-1, 40 weeks: HbA1c fell 1.7 to 1.8 points vs 0.1 on placebo[2]
Boxed warning	The same on both: risk of thyroid C-cell tumors, seen in rats, human relevance unknown. Not for anyone with a personal or family history of medullary thyroid carcinoma or with MEN 2.[1][2]
Lilly's self-pay price (November 2026)	Vials or KwikPen through LillyDirect: $299 a month for 2.5 mg, $399 for 5 mg, $449 for 7.5 to 15 mg with on-time refills[5]	Single-dose pen through LillyDirect: starting at $499 a month at every strength[6]
Medicare Part D	Not for weight management alone; can be covered for sleep apnea, often with prior authorization[7][8]	Covered on many Part D plans for type 2 diabetes, Lilly says[9]

For the full picture of the molecule, including every SURMOUNT and SURPASS trial and the label's warnings, see our tirzepatide reference page. For tirzepatide against semaglutide, the other big medicine in this family, see Zepbound vs Wegovy.

Is Zepbound the same as Mounjaro?

Chemically, yes. Both contain tirzepatide, a single molecule that activates the receptors for two gut hormones, GIP and GLP-1, and both come in the same six strengths, 2.5, 5, 7.5, 10, 12.5 and 15 mg.^[1][2] Both are once-weekly injections under the skin, with no food rule: the Zepbound label says any time of day, with or without meals.^[1]

Legally, they are two products. The FDA approved them under separate applications, Mounjaro under NDA 215866 and Zepbound under NDA 217806, each with its own label, its own approved uses and its own trials behind those uses.^[3] So "the same drug" is true of the molecule, and "different medicines" is true of everything that follows from the label: who it is approved for, how a plan covers it and what it costs.

Lilly also sells a different pill for weight management, Foundayo. It is a different molecule, orforglipron, not a tablet form of tirzepatide; neither Zepbound nor Mounjaro comes as a pill.^[10][1]

What is the difference between Mounjaro and Zepbound?

• Approved uses. Mounjaro is approved to control blood sugar in type 2 diabetes and, since August 27, 2026, to lower cardiovascular risk in adults with type 2 diabetes at high risk. Zepbound is approved for chronic weight management and for moderate to severe obstructive sleep apnea in adults with obesity.^[3][2][1]
• Age. Mounjaro is approved for children 10 and older with type 2 diabetes, up to 10 mg a week. Zepbound is for adults.^[2][1]
• Maintenance dose. On the Zepbound label, 2.5 mg is only a starting dose and maintenance is 5, 10 or 15 mg. Since August 2026 the Mounjaro label also allows 2.5 mg as an ongoing dose for blood sugar control.^[1][2]
• Forms. Both have single-dose pens, single-dose vials and a 4-dose KwikPen; the Mounjaro label also lists a 4-dose multi-dose vial.^[1][2]
• Trials. Zepbound's approvals rest on the SURMOUNT trials, in people with obesity or overweight and in sleep apnea; Mounjaro's on the SURPASS trials, in people with type 2 diabetes.^[1][2]
• Coverage and price, set out below, which is where most people feel the difference.

Zepbound and Mounjaro dosing: what the labels say

Both labels raise the dose in 2.5 mg steps, no faster than every 4 weeks, to reduce digestive reactions.^[1][2] The schedules are reproduced so you can see what each label says, not so you can follow them yourself.

What the FDA labels say — not dosing advice; your prescriber sets your dose.^[1][2]

	Zepbound (weekly)	Mounjaro (weekly)
Starting dose	2.5 mg for 4 weeks	2.5 mg for 4 weeks
Steps	Up by 2.5 mg after at least 4 weeks on each dose	Up by 2.5 mg after at least 4 weeks on each dose
Maintenance	5, 10 or 15 mg for weight management; 10 or 15 mg for sleep apnea	Set for blood sugar control, including 2.5 mg since August 2026
Maximum	15 mg	15 mg in adults; 10 mg in children 10 and older

Do Zepbound and Mounjaro have the same side effects?

The same molecule carries the same warnings: thyroid C-cell tumors in rats, pancreatitis, gallbladder disease, kidney injury from dehydration, serious allergic reactions, low blood sugar with insulin or a sulfonylurea, worsening diabetic eye disease and breathing in stomach contents under anesthesia.^[1][2] Digestive reactions are the most common on both, mostly while the dose is being raised.^[1]

Most common adverse reactions, drug vs placebo	Zepbound 5 / 10 / 15 mg (SURMOUNT trials)	Mounjaro 5 / 10 / 15 mg (SURPASS trials)
Nausea	25% / 29% / 28% vs 8%	12% / 15% / 18% vs 4%
Diarrhea	19% / 21% / 23% vs 8%	12% / 13% / 17% vs 9%
Vomiting	8% / 11% / 13% vs 2%	5% / 5% / 9% vs 2%
Constipation	17% / 14% / 11% vs 5%	6% / 6% / 7% vs 1%

Sources: the two labels.^[1][2] The columns come from different trials in different people, people with obesity or overweight in one and people with type 2 diabetes in the other, so they are not a ranking. The labels say rates from one set of trials cannot be compared directly with another's.^[1] Two more points from the Zepbound label: people taking birth control pills are advised to switch to a non-oral method, or add a barrier method, for 4 weeks after starting and after each dose increase; and hair loss was reported in 4% to 5% against 1% on placebo.^[1]

Insurance: why is Mounjaro covered and Zepbound not?

Because plans cover a use, not a molecule. A prescription for Mounjaro is written for type 2 diabetes; a prescription for Zepbound is usually written for chronic weight management, a use Medicare cannot cover and many employer plans do not. The pieces, as of November 13, 2026:

• Medicare Part D is barred by law from covering drugs used for obesity alone.^[7] Lilly says Mounjaro is covered on many Part D plans for type 2 diabetes.^[9]
• Zepbound for sleep apnea. After the December 2024 approval, CMS said "current Medicare Part D and Medicaid coverage rules apply," meaning Part D plans can cover Zepbound for that use and may require prior authorization to confirm it.^[8]
• The Medicare GLP-1 Bridge, a CMS demonstration from July 1, 2026 to December 31, 2027, gives eligible Part D beneficiaries certain GLP-1 drugs for a $50 copay, with prior authorization.^[11] Lilly lists Zepbound under it.^[5]
• Employer plans. In KFF's 2026 survey, 18% of firms with 200 or more workers covered GLP-1 medications used mainly for obesity.^[12] The plan's formulary and its prior authorization rules decide the rest.

Lilly's savings cards follow the same logic. The Mounjaro card requires a prescription "for an FDA-label-consistent use" and excludes anyone on Medicare, Medicaid or other government coverage.^[9]

How much do Zepbound and Mounjaro cost?

Prices change often. These are Lilly's own figures as of November 13, 2026.

• Zepbound, self-pay: vials and multi-dose KwikPens are sold only through LillyDirect, with a prescription.^[13] The price is $299 a month for 2.5 mg, $399 for 5 mg, and $449 for 7.5 to 15 mg under an offer that requires refilling on time; otherwise $499 for 7.5 mg and $699 for 10 to 15 mg.^[5]
• Zepbound, with commercial insurance: the single-dose pen can be as little as $25 with coverage, or as low as $499 a month without it, under a savings card that ends December 31, 2026.^[5]
• Mounjaro, self-pay: LillyDirect sells Mounjaro single-dose pens starting at $499 a month, the same at every strength from 2.5 mg to 15 mg, with a prescription.^[6]
• Mounjaro, with commercial insurance: as little as $25 for up to a 3-month fill when the plan covers it, or as low as $499 for a 1-month fill when it does not, under a savings card that ends December 31, 2026.^[9]

So at the starting and middle doses, paying directly for Zepbound vials or KwikPens costs less than paying directly for Mounjaro pens. Compounded tirzepatide is neither product: it is not FDA-approved, and what that means is in compounded GLP-1s explained.

Are Zepbound and Mounjaro interchangeable?

Not officially. What the labels and Lilly say:

• Not together. The Zepbound label says not to use it with other tirzepatide-containing products, which includes Mounjaro, or with any GLP-1 receptor agonist.^[1]
• No substitution rule. Neither label says one may be swapped for the other, and each is approved for its own uses only.^[1][2]
• Coverage follows the label. Plans and Lilly's savings cards tie coverage to the approved use, and Part D plans may use prior authorization to confirm it.^[9][8]

Whether someone moves from one to the other, at what dose and when, is a prescriber's decision. The matching strengths make the question look simpler than it is: the right product depends on the diagnosis, the plan and the person.

What to eat on either one

The Zepbound label pairs it with a reduced-calorie diet and more activity but names no diet.^[1] The 2025 joint advisory from four US medical and nutrition societies sets the priorities for every GLP-1 medication: protein first, small nutrient-dense meals, fiber from food, deliberate fluids and strength training to protect lean mass.^[14] Our pages go one question at a time:

• What to eat on Zepbound or Mounjaro: a small-appetite day, with amounts.
• How much protein on a GLP-1, by body weight, and the protein calculator.
• What to eat on queasy days, for the weeks after a dose step.
• The semaglutide side of the family: semaglutide (Ozempic, Wegovy).
• Every GLP-1 medication, approved and in trials, on one map: GLP-1 medications explained.

For transparency about why this page exists on our site: we make one product, Zornava Replenish, a lemon-lime daily hydration and nutrient powder for lighter appetite days, including for people on GLP-1 medications. It is a dietary supplement, not a medication, and it does not replace or imitate any medicine on this page. It is not on sale yet; early access opens February 9, 2027, and the early-access list is open now.